Latest News and Press Releases

Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two...

Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves...

Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety...

Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the Year ended 30 June 2021 Record pre-R&D operating profit ahead of market expectations...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Trading update Operating profit strong and expected to be well ahead of market expectationsExpenses for 2021 significantly...

 Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Preliminary Results for the year ended 30 June 2020 Record level of pre R&D operating profit supported by robust sales...

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”), Saiba AG(“Saiba”) and DeepVax GmbH (“DeepVax”) Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to...

Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)Interim Results for the six months ended 31 December 2019 Record level of operating profit pre R&D supported by strong...

                                                         Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Allergy Therapeutics publishes encouraging new data for peanut allergy...

Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the...